1,789 results on '"Laurent-Puig, Pierre"'
Search Results
2. Clinical value of sequential circulating tumor DNA analysis using next-generation sequencing and epigenetic modifications for guiding thermal ablation for colorectal cancer metastases: a prospective study
3. PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up
4. Peritoneal Tumour DNA in Peritoneal Fluid: Emerging Tool for Peritoneal Metastasis Detection
5. Wnt, glucocorticoid and cellular prion protein cooperate to drive a mesenchymal phenotype with poor prognosis in colon cancer
6. FedECA: A Federated External Control Arm Method for Causal Inference with Time-To-Event Data in Distributed Settings
7. Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases
8. Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis
9. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma
10. Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial
11. Molecular features and clinical actionability of gene fusions in colorectal cancer
12. Early-Onset colorectal Cancer: From the laboratory to the clinic
13. Prognostic value of BRCA1 promoter methylation for patients with epithelial ovarian cancer
14. Lynch syndrome: influence of additional susceptibility variants on cancer risk
15. Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts
16. Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR)
17. Features of colorectal adenomas among young patients with Lynch syndrome according to path_MMR: Results from the PRED-IdF registry
18. Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival
19. Circadian rhythm and circulating cell-free DNA release on healthy subjects
20. Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration
21. A novel Chr1-miR-200 driven whole transcriptome signature shapes tumor immune microenvironment and predicts relapse in early-stage lung adenocarcinoma
22. Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab
23. Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer
24. Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study
25. Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial
26. Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers
27. A proof of concept for targeting the PrPC - Amyloid β peptide interaction in basal prostate cancer and mesenchymal colon cancer
28. Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma?
29. Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer
30. Potential competing risk of death in older high-risk endometrial carcinoma patients: Results from a multicentric retrospective cohort
31. FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer
32. SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer
33. BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma
34. Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations
35. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer
36. Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer
37. An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution
38. Place des inhibiteurs de PARP dans le traitement des cancers de l’endomètre et du col de l’utérus
39. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials
40. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS)
41. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial
42. Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study
43. Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)
44. Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC
45. Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey
46. PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
47. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial
48. Olaparib in the Setting of Radiotherapy-Associated Sarcoma: What Can Precision Medicine Offer For Rare Cancers?
49. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials
50. Contributors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.